Company Securities Exchange Announcements
2020 ASX Announcements
Immuron Sars-CoV-2 Research Agreement with Monash University (15/12/20)
Change of Director's Notice (26/11/20)
Immuron receives AUD $358,280 R&D tax concession refund (24/11/20)
Change of Director's Interest Notivce (x5) (17/11/20)
Change in substantial holding (16/11/20)
Proposed Issue of Securities (13/11/20)
US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine (9/11/20)
2020 AGM Presentation (29/10/20)
Immuron filed XBRL data with the SEC (29/10/20)
Form 20-F filed with the SEC (29/10/20)
Change in substantial holding (19/10/20)
Immuron Travelers' Diarrhea market update (13/10/20)
Time of AGM clarification (30/09/20)
Corporate Governance Statement (25/09/20)
Notice of Annual General Meeting/Proxy Form (25/09/20)
Annual Report to shareholders (25/09/20)
Change in substantial holding (16/09/20)
Change in substantial holding (04/09/20)
Appendix 4E and 2020 Financial Report (01/09/20)
Change in substantial holding (28/08/20)
Change of Director's Interest Notice (PA&SA) (21/08/20)
Change in substantial holding (21/08/20)
Change in substantial holding (19/08/20)
Change in substantial holding (12/08/20)
Change in substantial holding (05/08/20)
Change in substantial holding (31/07/20)
Appendix 2A and 708A Notice (29/07/20)
Proposed issue of Securities – IMC (29/07/20)
Change in substantial holding (28/07/20)
Proposed issue of Securities - IMC (27/07/20)
US SEC Form 6-K Filing (24/07/20)
Prospectus Supplement (24/07/20)
Appendix 2A and 708A Notice (24/07/20)
Closing of US$20 Million Registered Direct Offering (24/07/20)
Proposed issue of Securities – IMC (23/07/20)
Immuron Announces US$20.0 Million Registered Direct Offering (22/07/20)
Immuron Reports Neutralizing activity Against SARS-CoV-2 (21/07/20)
US DoD Receives FDA Guidance on clinical development plans (20/07/20)
Appendix 2A and 708A notice (03/07/20)
Proposed issue of Securities – IMC (01/07/20)
Change in substantial holding (26/06/20)
Change in substantial holding (25/06/20)
Change of Director's Interest Notice (RA) (23/06/20)
Change of Director's Interest Notice (DP) (23/06/20)
Appendix 2A and 708A notice (23/06/20)
Change in substantial holding (23/06/20)
Proposed issue of Securities – IMC (22/06/20)
Proposed issue of Securities – IMC (22/06/20)
Change in substantial holding (22/06/20)
IMC & CSIRO to produce oral therapeutic for DoD evaluation (19/06/20)
Change in substantial holding (GL) (19/06/20)
Change of Director's Interest Notice PA (19/06/20)
Change in substantial holding (19/06/20)
Change in substantial holding (18/06/20)
Change in substantial holding (17/06/20)
Appendix 2A and 708A notice (16/06/20)
Ceasing to be a substantial holder (16/06/20)
Change in substantial holding (16/06/20)
Proposed issue of Securities – IMC (15/06/20)
Change of Director's Interest Notice (DP) (12/06/20)
Response to ASX Price Query (10/06/20)
US Defense requests FDA meeting (09/06/20)
Immuron Board Relinquish Cash Payment of Fees (27/04/20)
Immuron Global Sales Up 60% (20/04/20)
Final Director's Interest Notice (GJ) (26/03/20)
Resignation of Managing Director and cuts amid Covid19 (25/03/20)
Immuron Provides Update on First Half of FY20 Results (02/03/20)
Half Yearly Report and Accounts (26/02/20)
Change in substantial holding (12/02/20)
North American Travelan sales up 98% to Dec 2019 (28/01/20)
Change of Share Registry (20/01/20)
Immuron CEO to present at Biotech Conference in SFO (08/01/20)
